Ken Griffin Tg Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$17.21 - $25.28 $321,827 - $472,736	18,700 Added 7.51%	267,800 $6.26 Million
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $1.34 Million - $1.93 Million	-100,400 Reduced 28.73%	249,100 $4.43 Million
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $4.01 Million - $6.56 Million	-308,100 Reduced 46.85%	349,500 $5.32 Million
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $1.21 Million - $3.4 Million	180,500 Added 37.83%	657,600 $11.2 Million
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $693,880 - $2.2 Million	83,000 Added 21.06%	477,100 $3.99 Million
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $897,840 - $2.03 Million	58,000 Added 17.26%	394,100 $9.79 Million
Q1 2023 May 15, 2023	SELL	$10.23 - $19.34 $2.9 Million - $5.48 Million	-283,300 Reduced 45.74%	336,100 $5.05 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $1.63 Million - $3.85 Million	325,400 Added 110.68%	619,400 $7.33 Million
Q3 2022 Nov 14, 2022	SELL	$4.57 - $8.4 $338,637 - $622,440	-74,100 Reduced 20.13%	294,000 $1.74 Million

338

87.7M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.67B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.